These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 20873946)

  • 1. Emerging oral agents for multiple sclerosis.
    Fox EJ
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
    Hecht B
    Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current treatment of multiple sclerosis].
    Csépány T
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral treatment for multiple sclerosis.
    Killestein J; Rudick RA; Polman CH
    Lancet Neurol; 2011 Nov; 10(11):1026-34. PubMed ID: 22014437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging disease-modifying oral therapies for multiple sclerosis.
    Losy J; Kalinowska-Łyszczarz A
    J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Emerging therapies for multiple sclerosis].
    de Lorenzo-Pinto A; Rodríguez-González CG; Ais-Larisgoitia A
    Med Clin (Barc); 2013 Jan; 140(2):76-82. PubMed ID: 22766059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New and emerging disease modifying therapies for multiple sclerosis.
    Saidha S; Eckstein C; Calabresi PA
    Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis therapeutic pipeline: opportunities and challenges.
    Krieger S
    Mt Sinai J Med; 2011; 78(2):192-206. PubMed ID: 21425264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.
    Mulakayala N; Rao P; Iqbal J; Bandichhor R; Oruganti S
    Eur J Med Chem; 2013 Feb; 60():170-86. PubMed ID: 23291119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA; Kantesaria PP; McDevitt LM
    Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy.
    Hohlfeld R; Barkhof F; Polman C
    Neurology; 2011 Feb; 76(8 Suppl 3):S28-37. PubMed ID: 21339488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New disease-modifying and symptomatic therapies for multiple sclerosis].
    Weise G; Buttmann M
    MMW Fortschr Med; 2012 Apr; 154(7):64-6. PubMed ID: 22558878
    [No Abstract]   [Full Text] [Related]  

  • 15. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A; Castilló J; Montalban X
    Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Will the newer oral MS agents be welcomed by managed care organizations?
    Lipsy RJ
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S227-33. PubMed ID: 20873947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options for multiple sclerosis: current and emerging therapies.
    Gawronski KM; Rainka MM; Patel MJ; Gengo FM
    Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Emerging treatments for multiple sclerosis].
    Nau JY
    Rev Med Suisse; 2010 Jun; 6(251):1162-3. PubMed ID: 20572362
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging oral drugs for relapsing-remitting multiple sclerosis.
    Gasperini C; Ruggieri S
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.